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Leucine-rich repeat kinase 2 is a large protein with implications in genetic and
sporadic causes of Parkinson’s disease. The physiological functions of LRRK2 are
largely unknown. In this report, we investigated whether LRRK2 alters neural transport
using live-cell imaging techniques and human neuroblastoma SH-SY5Y cells. Our
results demonstrated that expression of the PD-linked mutant, LRRK2-R1441C,
induced mitochondrial, and lysosomal transport defects in neurites of SH-SY5Y cells.
Most importantly, recently identified GTP-binding inhibitors, 68 and FX2149, can
reduce LRRK2 GTP-binding activity and attenuates R1441C-induced mitochondrial and
lysosomal transport impairments. These results provide direct evidence and an early
mechanism for neurite injury underlying LRRK2-induced neurodegeneration. This is the
first report to show that LRRK2 GTP-binding activity plays a critical role during neurite
transport, suggesting inhibition of LRRK2GTP-binding could be a potential novel strategy
for PD intervention.
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INTRODUCTION
Parkinson’s disease (PD) is a common progressive neurodegenerative disease with movement
disorder. Human PD cases often display a loss of dopaminergic neurons in the substantia nigra
and the presence of protein inclusions (Lewy bodies) in the brain (Dauer and Przedborski, 2003;
Cookson, 2010). Although the pathogenesis of PD is not completely clear, mutations in the leucine-
rich repeat kinase 2 (LRRK2) represent the most common known cause of PD to date (Klein and
Lohmann-Hedrich, 2007; Paisán-Ruiz et al., 2013). LRRK2-associated PD cases have pleomorphic
pathology, however the physiological function of LRRK2 is largely undetermined. LRRK2 is a large
286 kDa cytoplasmic protein and contains several functional domains (Li et al., 2011). Studies
suggest that LRRK2 is involved in multiple cellular processes, including cytoskeletal organization,
neuronal outgrowth, mitochondrial dynamics, autophagy, endocytosis, and protein interactions
(Mata et al., 2006; Raquel Esteves et al., 2014). PD-linked LRRK2 mutations cause neuronal
degeneration although the underlying mechanisms remain elusive.
Disease-linkedmutations mostly occur in one of LRRK2’s two enzymatic sites: a GTPase domain
and a kinase domain (Lee et al., 2012; Martin et al., 2014). These regions have shown considerable
overlap and interplay in PD pathology in previous studies (Gilsbach and Kortholt, 2014; Raquel
Esteves et al., 2014). The majority of LRRK2 PD mutations can lead to increased kinase activity
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and altered GTP binding/GTPase activities (Smith et al., 2006;
Xiong et al., 2012). The LRRK2-R1441C mutation occurs
in the GTPase domain, and mutations at this residue have
previously shown a combination of decreased GTPase activity,
a possible increase in GTP-binding affinity, and a subsequently
overactivated kinase activity (Xiong et al., 2012; Liao et al., 2014;
Raquel Esteves et al., 2014). Studies on LRRK2 kinase andGTPase
domain inhibitors suggest that LRRK2 kinase and GTPase
functions play critical roles in neurodegeneration. Our recently
identified novel GTP-binding inhibitors (Li et al., 2014, 2015)
provide useful pharmacological probes to investigate LRRK2
pathophysiological roles in PD pathogenesis.
Neural transport, in particular axonal transport, is especially
necessary in maintaining healthy neurons as neurons are highly
polarized cells which utilize specific motor proteins to travel
in directions away from the cell body (anterograde) or toward
the cell body (retrograde) along cytoskeletons composed of
microtubules (Fu and Holzbaur, 2014; Maday et al., 2014).
Defects in axonal transport can lead to disruption in energy
homeostasis, impaired protein clearance pathways, neurite
shortening, and eventual cell death (Fu and Holzbaur, 2014;
Maday et al., 2014). Impaired neural transport has been shown
to contribute to the pathogenesis of neurodegenerative disorders,
including Alzheimer’s disease (AD), amyotrophic lateral sclerosis
(ALS), and hereditary spastic paraplegia (HSP) (Chevalier-Larsen
andHolzbaur, 2006). Recent studies suggest that neural transport
(especially axonal transport) impairment may also contribute to
mutant alpha-synuclein toxicity and have implications in PD
pathology (Kim-Han et al., 2011; Lu et al., 2014; Koch et al., 2015).
LRRK2 has been previously shown to interact with microtubules
and some cytoskeleton proteins (Kawakami et al., 2012; Caesar
et al., 2013; Beilina et al., 2014; Law et al., 2014). A recent study
has reported that LRRK2 interacts with a group of Rab GTPases
that play critical roles in cell membrane trafficking (Dodson et al.,
2012; Steger et al., 2016). Computer based predictions of LRRK2’s
interactome suggest that a cluster of its interactors are more
likely involved in regulating cell transport/localization and cell
organization (Manzoni et al., 2015). LRRK2 has been shown to
regulate neuronal outgrowth and intracellular events necessary
for maintaining healthy neurons (Ramonet et al., 2011; Su and
Qi, 2013).
In this study, we are interested in investigating whether
PD-linked LRRK2 mutations alter neural transport and
whether inhibition of LRRK2 enzymatic activities plays a
role in this process. We observed the movement of transport
cargos including mitochondria and lysosomes in differentiated
neuroblastoma SH-SY5Y cells by using live-cell-imaging
approaches. Our studies not only provide the mechanisms of
early neurodegeneration but also provide a potential novel
therapeutic strategy for intervention.
MATERIALS AND METHODS
Materials and Reagents
Cell culture media and transfection reagents (LipofectAMINE
and Plus reagent) were purchased from Invitrogen (Carlsbad,
CA). Compound 68 was custom ordered from Chembridge and
FX2149 and FX2151 were synthesized by Dr. Fengtian Xue’s
group. Compounds were dissolved in 0.1% DMSO for live-cell
imaging and GTP-binding experiments. MitoTracker Orange
and LysoTracker Red were from Molecular Probes at Thermo
Fisher Scientific, and were dissolved in DMSO for live-cell
imaging experiments.
Cell Culture and LRRK2 Transfection
SH-SY5Y human neuroblastoma cells (passage 4–10) were from
ATCC (Manassas, VA, USA), contain dopamine, and were
grown in OptiMem I media with 10% FBS and antibiotics
as described previously. In this condition, SH-SY5Y cells
display differentiated neuron features with neuritic processes
for neural transport studies (Plowey et al., 2008). The Flag-
wild-type and Flag-R1441C pcDNA3.1-LRRK2 constructs were
described previously (Smith et al., 2006; Ko et al., 2009). pMax-
GFP was from Clontech. Transfections were performed using
LipofectamineTM and PLUSTM Reagents (Invitrogen) according
to the manufacturer’s recommendations.
LRRK2 Neuritic Injury Assays
SH-SY5Y cell neuritic injury assays were conducted as described
(Smith et al., 2005; Yang et al., 2012). GFP and various pcDNA3.1-
LRRK2 plasmids were transfected into SH-SY5Y cells at a 1:15
ratio for 24 h in OptiMem I media supplemented with 10%
FBS and then changed to DMEM with N2 supplement for an
additional 24 h. Under these conditions, above 85% of GFP
positive neurons also expressed LRRK2 variants by anti-LRRK2
immunostaining as described previously (Smith et al., 2005).
Fluorescence microscopy was used to measure cell viability fields
by counting the healthy viable cells, defined by possessing at
least one smooth extension (neurite) twice the length of the
cell body from nine randomly selected fields. The experiments
were repeated three times in duplicate. The quantification for
LRRK2 neurite injury was performed by an investigator blinded
to transfection groups.
GTP Binding Activity Assay and Western
Blot Analysis
SH-SY5Y cells transiently transfected to express wild-type,
LRRK2-R1441C, or empty vector as described above were
harvested. Lysates were incubated with 68 (100 nM) for 1 h
at 4◦C, then precipitated with GTP-agarose (Sigma) for an
additional 1 h at 4◦C. Agarose samples were diluted in 2X
Loading buffer (Invitrogen) and 3% βME and denatured in 85◦C
for 5 min. Samples were resolved using 4–12% NuPAGE Bis-Tris
gels and subjected to Western blot analysis using anti-Flag and
anti-actin antibodies (Sigma) (Li et al., 2014, 2015).
Live-Cell Imaging and Transport Analysis
Procedures were performed as described previously with slight
modification (Cherra et al., 2013; Das et al., 2014; Klinman
and Holzbaur, 2015). SH-SY5Y cells were plated and cultured
for 1 day prior to transfection. Cells were co-transfected with
various LRRK2 plasmids and pMax-GFP at a 1:15 ratio using
LipofectamineTM and PLUSTM Reagents (Invitrogen) according
to the manufacturer’s protocol. After 4 h of transfection, the cells
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were maintained in 10% FBS OptiMem I medium for 48 h, then
fluorescent dye [MitoTracker Orange (125 nM) or LysoTracker
Red (100 nM)] was added for 30 min. Before imaging, the
cells were washed once with phenol red-free OptiMem I and
kept in this phenol red-free media for transport assays. For
inhibitor treatment, 68 (100 nM), FX2149 (100 nM), FX2151
(100 nM), or 0.1% DMSO was added to growth media 4 h
post-transfection, and replaced every 12 h for a total of 48
h prior to imaging. Images were taken using a Zeiss Avixon
Camera under a computer controlled fluorescent microscope.
Images were taken every 15 s for a total of 5 min. Images were
compiled into a time-lapse sequence using NIH ImageJ software,
and fluorescent puncta in healthy cell neurites were tracked using
the MTrackJ plugin (Biomedical Imaging Group Rotterdam,
Meijering et al., 2012). Puncta were classified as anterograde
(≥2 micron displacement away from cell body), retrograde
(≥2 micron displacement toward cell body), or stationary (<2
microns displacement). Puncta were recorded at their farthest
displacement in either direction over the course of the time-
lapse sequence, and puncta were counted as both anterograde
and retrograde if a displacement of at least 2 microns occurred
in the opposite direction during this time. To focus specifically
on the interruption of highly processive motility, three puncta
per cell traveling the farthest in both anterograde and retrograde
directions were tracked for run lengths.
Data Analysis
Quantitative data represent arithmetic means ± SEM from at
least three separate experiments for each condition. Live-cell
images were taken for at least three separate experiments with
at least four cells per experiment for each condition. Only
viable GFP-expressing cells were included in these analyses.
Statistically significant differences among groups were analyzed
by ANOVA with post hoc Tukey’s test using Sigmastart 3.1
statistical software. A p < 0.05 was considered significant.
RESULTS
LRRK2-R1441C Caused Neurite Injury in
SH-SY5Y Cells
Previous studies reported that the LRRK2-R1441 mutant
causes disrupted neurite outgrowth, leads to decreased neuritic
branching in PD models using cultured cell lines or primary
neurons (MacLeod et al., 2006; Heo et al., 2010; Cherra
et al., 2013; Tagliaferro et al., 2015). Here, we used SH-
SY5Y cells transiently transfected with Flag-wild-type and Flag-
R1441C-LRRK2 constructs as a cell model to express the
LRRK2 variants. SH-SY5Y were grown in the media (10% FBS,
OptiMem I media) to display mature neuron morphology with
smooth neurite processes. Western blot analysis showed that
LRRK2 variants were expressed well after 2–3 days transfection
(Figure 1A). Consistent with previous reports (Smith et al., 2005,
2006; Tagliaferro et al., 2015), cells expressing LRRK2-R1441C
displayed noticeable neuritic injury (beading) and impaired
neurite complexity after 48 h as compared with vector controls
(Figure 1B). The percentage of cells with at least one neuritic
injury (beading) was significantly increased in those expressing
FIGURE 1 | LRRK2-R1441C mutation caused neurite injury in PD cell
model. SH-SY5Y cells were co-transfected with GFP and various Flag-tagged
pcDNA3.1-LRRK2 plasmids at a 1:15 ratio as described in the method
section. (A) Cell lysates were harvested and subjected to western blot analysis
using anti-Flag and anti-actin antibodies. (B,C) Two days post-transfection,
cells were imaged for GFP fluorescence. Nine images were taken in separate
fields for each experiment. (B) Shown are representative cell images in each
experiment group. (C) Neurite injury was measured by dividing the number of
viable GFP positive cells with at least one smooth extension equal to twice the
length of the cell body and at least one neuritic swelling by the total number of
healthy GFP-positive cells with at least one neurite (F = 70.88). *p < 0.05 by
ANOVA compared to vector control. ***p < 0.001 by ANOVA compared to
vector control.
LRRK2-R1441C compared with empty vector control cells. Wild-
type LRRK2 overexpression only displayed a moderate neuritic
injury (Figure 1C).
LRRK2-R1441C Disrupted Mitochondrial
Transport in SH-SY5Y Neurites
To assess whether mutant LRRK2 alters neural transport, human
SH-SY5Y cells were employed to track mitochondrial transport
using a live-cell imaging assay. Mitochondria were labeled with
MitoTracker Orange and defined as stationary (<2 micron
displacement), anterograde (≥2 micron displacement away from
cell body), or retrograde (≥2 micron displacement toward
cell body) (Figure 2A). Kymographs generated from time-lapse
image sequences show a greater tendency for mitochondria
in LRRK2-R1441C expressing cells to remain stationary as
compared with vector controls or cells expressing wild type-
LRRK2 (Figure 2B). LRRK2-R1441C also significantly decreases
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FIGURE 2 | LRRK2-R1441C induced neuritic mitochondria transport impairments. SH-SY5Y cells co-transfected with GFP and various pcDNA3.1-LRRK2
plasmids at a 1:15 ratio for 48 h. Prior to imaging, cells were stained with MitoTracker Orange for 30 min. Cells were imaged every 15 s for a total of 5 min as
mentioned in detail in methods section. (A) An image depicts time-lapse live-cell imaging technique used for measuring neuritic mitochondrial transport. Mitochondria
in neurites of GFP-positive SH-SY5Y cells were traced using images captured during time progression, and classified as stationary (yellow), anterograde (green), or
retrograde (red) as described in methods section. (B) Kymographs generated from live-cell imaging assays demonstrating typical neuritic mitochondria movement for
vector, LRRK2-WT, and LRRK2-R1441C conditions. (C) Quantification of percentage of mitochondria traveling less than 2 microns (stationary), greater than two
microns away from cell body (anterograde), or greater than two microns toward cell body (retrograde) in cells expressing GFP for each condition. *p < 0.05 by ANOVA
compared to vector control. {F (2, 5) = 15.49; F (2, 5) = 10.32; F (2, 5) = 22.65 for stationary, anterograde, retrograde, respectively}. (D) Quantification of total,
anterograde, and retrograde run lengths of mitochondria traveling at least 2 microns in GFP-expressing cells for each condition. *p < 0.05 by ANOVA compared to
vector control. {F (2, 66) = 3.354; F (2, 21) = 0.1804; F (2, 42) = 3.271 for total, anterograde, retrograde run length, respectively}.
the number of mitochondria traveling in both anterograde
and retrograde directions compared with vector controls
(Figure 2C). Cells expressing wild type-LRRK2 did not change
compared with control cells. In order to assess the processive
nature of mitochondria in the above conditions, run lengths
of mitochondria traveling at least 2 microns were measured.
Cells expressing LRRK2-R1441C showed a significant decrease
in total run length of motile mitochondria compared with cells
expressing vector or wild type-LRRK2, with a significant decrease
in the retrograde transport (Figure 2D). Wild-type LRRK2 did
not affect observed mitochondrial transport in SH-SY5Y cells
under live-cell imaging (Figures 2C,D), possibly due to cell
auto-modulation to balance the normal transport.
68 and FX2149, GTP-Binding Inhibitors,
Attenuated LRRK2-R1441C-Induced
Mitochondrial Transport Defects
As LRRK2-R1441Cmutations occur within its GTPase domain, a
novel LRRK2-specific GTP-binding inhibitor recently discovered
by our lab (Li et al., 2014, 2015) was used to assess whether it alters
mitochondria transport in cells expressing LRRK2-R1441C.
Consistent with previous studies (Li et al., 2014), a GTP-binding
inhibitor, compound 68, significantly reduces LRRK2-R1441C
binding with GTP, while its structural analog, a negative control
compound, FX2151, did not (Figures 3A,B). Treatment with 68
did not alter the mitochondrial transport in vector control or
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FIGURE 3 | A GTP-binding inhibitor, 68, improved mitochondria transport impairment in LRRK2-R1441C cells. SH-SY5Y cells co-transfected with GFP and
either Flag-LRRK2-R1441C, Flag-LRRK2-WT, or vector plasmids at a 1:15 ratio were treated with 68 at 100 nM at 4 h post-transfection for 48 h. (A,B). GTP-binding
assay of cell lysates. (A) Western blots of GTP-binding assays. R1441C/K1347A double mutant represents a non-GTP-binding control lysate. FX2151 represents a 68
analog with no effect on GTP-binding activity (inactive control). (B) Quantification of GTP-binding activity from three repeated GTP binding assays. *p < 0.05 by
ANOVA compared to R1441C with vehicle treatment. (C) Mitochondria events were quantified as stationary, anterograde, or retrograde and expressed as a
percentage of total mitochondria for various groups as indicated., *p < 0.05 by ANOVA compared to vector control. {F (2, 5) =15.49; F (2, 5) =10.32; F (2, 5) = 22.65
for stationary, anterograde, retrograde, respectively}. #p < 0.05 by ANOVA compared to R1441C with vehicle treatment. {F (2, 6) =7.243; F (2, 6) = 0.9794; F (2, 6) =
20.42 for stationary, anterograde, retrograde, respectively}. (D) Quantification of total, anterograde, and retrograde run lengths of mitochondria traveling at least 2
microns in 68 treated, FX2151 treated, and DMSO treated GFP-expressing cells. *p < 0.05 by ANOVA compared to vector control. {F (2, 66) = 3.354; F (2, 21) =
0.1804; F (2, 42) = 3.271 for total, anterograde, retrograde run length, respectively}.
#p <0.05 by ANOVA compared to R1441C with vehicle treatment. {F (2, 47) =
3.468; F (2, 10) = 0.3281; F (2, 34) = 6.779 for total, anterograde, retrograde run length, respectively}.
LRRK2-WT cells (Figures 3C,D). Interestingly, 68 significantly
reduced the number of stationary mitochondria in cells
expressing LRRK2-R1441C.Moreover, 68 also improved LRRK2-
R1441C-induced impairments of anterograde and retrograde
mitochondrial movement in neurites (Figure 3C). 68 had more
of an effect on improving mitochondrial transport in the
retrograde direction, while only displaying a slight trend in
increasing anterograde movement but with no significance
(Figures 3C,D). Following treatment with another GTP-binding
inhibitor, FX2149, the number of stationary mitochondria was
likewise decreased in the RC condition in favor of increased
anterograde and retrograde levels (Figure 4). The run lengths
were also increased in the RC level toward vector controls
following FX2149 treatment, significantly in the retrograde
direction. In contrast, there was no effect with negative control
compound FX2151 on mitochondrial transport.
LRRK2-R1441C Impaired Lysosomal
Transport in SH-SY5Y Neurites Is Improved
by 68 and FX2149
Lysosome transport patterns were observed using a live-
cell imaging approach and characterized as either stationary,
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FIGURE 4 | A GTP-binding inhibitor FX2149 improved mitochondrial transport impairment in LRRK2-R1441C cells. SH-SY5Y cells co-transfected with
GFP and either Flag-LRRK2-R1441C, Flag-LRRK2-WT, or vector plasmids at a 1:15 ratio were treated with FX2149 at 100 nM at 4 h post-transfection for 48 h. (A)
Mitochondria events were quantified as stationary, anterograde, or retrograde and expressed as a percentage of total mitochondria for DMSO and FX2149 treatments.
*p < 0.05 by ANOVA compared to vector control. {F (2, 5) = 15.49; F (2, 5) = 10.32; F (2, 5) = 22.64 for stationary, anterograde, retrograde, respectively}. #p < 0.05 by
t-test compared to R1441C with vehicle treatment. {F (4) = 3.699; F (4) = 1.049; F (4) = 2.855 for stationary, anterograde, retrograde, respectively}. (B) Quantification
of total, anterograde, and retrograde run lengths of mitochondria traveling at least 2 microns in FX2149 treated and DMSO treated GFP-expressing cells. *p < 0.05 by
ANOVA compared to vector control. {F (2, 66) = 3.774; F (2, 21) = 0.1804; F (2, 42) = 3.271 for stationary, anterograde, retrograde run length, respectively}. #p < 0.05
by t-test compared to R1441C with vehicle treatment. {F (24) = 4.974; F (6) = 3.828; F (16) = 6.340 for stationary, anterograde, retrograde run length, respectively}.
anterograde, or retrograde as described above for mitochondrial
transport analysis. Expression of wild type-LRRK2 did not
alter lysosome transport compared with vector control cells
(Figure 5). In contrast, expression of LRRK2-R1441C mutant
significantly increased the number of stationary lysosomes
and decreased the number of lysosomes in both anterograde
and retrograde directions (Figures 5A–C). These results were
further validated by the run-length assays of lysosome transport
(Figure 5D). A significant decrease in total run lengths of
lysosomes traveling at least 2microns was seen in cells transfected
with LRRK2-R1441C (Figure 5D). LRRK2-R1441C caused more
reductions in the retrograde direction, while there was only a
slight trend in reduction with no significance in anterograde
movement in the run-length assays.
To assess the effect of 68 on LRRK2-linked lysosome
transport, 68 was used to treat cells expressing vector, LRRK2-
WT, and LRRK2-R1441C for 48 h. Treatment of 68 did not
alter lysosome transport in vector control or LRRK2-WT cells
(Figure 6). However, 68 significantly decreased stationary
lysosomes in cells expressing LRRK2-R1441C compared
with vehicle treated control cells (Figure 6A). Moreover, 68
significantly improved the R1441C-LRRK2-induced defects
in lysosome transport in both anterograde and retrograde
directions, compared with R1441C expressing cells treated
with vehicle alone (Figure 6). Treatment with FX2149 resulted
in a decrease in stationary lysosomes, like in the 68-treated
condition (Figure 7). A corresponding increase in anterograde
and retrograde lysosomes was observed. Lysosome run lengths
were significantly increased amongst anterograde and retrograde
organelles in the FX2149-treated condition compared to vehicle
treated RC cells. There was no effect on lysosome transport
following treatment with negative control compound FX2151.
DISCUSSION
The major findings of this study are that PD-linked GTPase
domain mutation LRRK2-R1441C causes impairments in the
neuritic transport of both mitochondria and lysosomes in SH-
SY5Y cells and that inhibition of GTP-binding with recently
identified pharmacological inhibitors, 68 and FX2149, improves
these transport defects. To our knowledge, this is the first report
that GTP-binding activity is involved in mitochondrial and
lysosomal cargo transport in neuritic processes. Our findings
provide novel insight into LRRK2-linked neuron degeneration
and a potential strategy for PD intervention through inhibition
of GTP-binding activity.
Neuritic injury has been shown to result from impaired
functions within neurons, including disruption of mitochondrial
energy homeostasis, protein clearance pathways, and
intracellular transport processes (Chevalier-Larsen and
Holzbaur, 2006; Sheng and Cai, 2012; Schwarz, 2013; Amaya
et al., 2015). Axon injury has been reported as one of the
early neuronal degeneration events occurring way before cell
body degeneration in a number of neurodegenerative diseases,
including PD (Chevalier-Larsen and Holzbaur, 2006; Maday
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FIGURE 5 | LRRK2-R1441C induced lysosome transport impairment. SH-SY5Y cells were co-transfected with GFP and various pcDNA3.1-LRRK2 plasmids at
a 1:15 ratio for 48 h. Prior to imaging, cells were stained with LysoTracker Red for 30 min. (A) A representative image depicts time-lapse live-cell imaging technique
used for measuring neuritic lysosomal transport. Lysosomes were traced using images captured during time progression, and classified as stationary (yellow),
anterograde (green), or retrograde (red). Kymographs generated from live-cell imaging assays demonstrating neuritic lysosome movement. Lysosomal events were
classified as stationary (yellow), anterograde (green), or retrograde (red). (B) Quantification of percentage of lysosomes traveling less than 2 microns (stationary),
greater than two microns away from cell body (anterograde), or greater than two microns toward cell body (retrograde) in cells expressing GFP for each condition.*p <
0.05 by ANOVA compared to vector control. {F (2, 7) = 8.184; F (2, 7) = 5.423, F (2, 7) = 5.275 for stationary, anterograde, retrograde, respectively}. (C) Quantification
of total, anterograde, and retrograde run lengths of lysosomes traveling at least 2 microns in GFP-expressing cells for each condition. *p < 0.05 by ANOVA compared
to vector control. {F (2, 103) = 4.249; F (2, 32) = 0.4790; F (2, 68) = 4.707 for total, anterograde, retrograde run length, respectively}.
et al., 2014). Neural transport, especially axonal transport, is
necessary for neuronal functions including mitochondrial energy
balance, autophagic-lysosomal degradation, and transportation
of vesicles and other cargos.
Under physiological conditions, about two-thirds of axonal
mitochondria are in a stationary phase, whereas the remaining
third are split equally among mitochondria traveling in
anterograde or retrograde directions (Sheng and Cai, 2012;
Schwarz, 2013; Maday et al., 2014). About half of axonal
lysosomes experience diffusive, random back-and-forth motion
of insignificant distances, whereas the other half undergo
directed motion equally in either anterograde or retrograde
directions (Bandyopadhyay et al., 2014; Maday et al., 2014).
Our results demonstrated that expression of the PD-linked
mutant, LRRK2-R1441C, significantly increases the number
of stationary mitochondria in the neurties of SH-SY5Y cells.
Moreover, LRRK2-R1441C reduced the number and distance
of mitochondria being transported in both anterograde and
retrograde directions. Interestingly, previous reports showed
that the LRRK2-G2019S kinase domain mutant does not affect
mitochondrial transport in cultured neurons (Godena et al.,
2014), suggesting that kinase domain function may not be
involved in neural transport. A number of reports showed that
disease-linked LRRK2mutants causemitochondrial dysfunctions
(Cherra et al., 2013; Su and Qi, 2013; Saez-Atienzar et al., 2014;
Su et al., 2015), however the underlying mechanisms are unclear.
Our results suggest that impairment of the neuritic transport of
mitochondria could be one of the early events and mechanisms
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FIGURE 6 | 68 improved LRRK2-R1441C-induced lysosome transport defects. SH-SY5Y cells co-transfected with GFP and either Flag-LRRK2-R1441C,
Flag-LRRK2-WT, or vector plasmids at a 1:15 ratio were treated with 68 at 100 nM at 4 h post-transfection for 48 h. (A) Lysosomal events were quantified as
stationary, anterograde, or retrograde and expressed as a percentage of total lysosomes for DMSO, FX2151 (100 nM), and 68 treatments (100 nM). *p < 0.05 by
ANOVA compared to vector control. {F (2, 7) = 8.184; F (2, 7) = 5.423, F (2, 7) = 5.275 for stationary, anterograde, retrograde, respectively}.
#p < 0.05 by ANOVA
compared to R1441C with vehicle treatment. {F (2, 6) = 15.66; F (2, 6) = 19.57, F (2, 6) = 6.392 for stationary, anterograde, retrograde, respectively}. (B) Quantification
of total, anterograde, and retrograde run lengths of lysosomes traveling at least 2 microns in 68 treated, FX2151 treated, and DMSO treated GFP-expressing cells. *p
< 0.05 by ANOVA compared to vector control. {F (2, 103) = 4.249; F (2, 32) = 0.4790; F (2, 68) = 4.707 for total, anterograde, retrograde run length, respectively}.
#p
< 0.05 by ANOVA compared to R1441C with vehicle treatment. {F (2, 70) = 11.91; F (2, 20) = 8.789; F (2, 47) = 4.666 for total, anterograde, retrograde run length,
respectively}.
FIGURE 7 | FX2149 restored lysosomal transport in LRRK2-R1441C cells. SH-SY5Y cells co-transfected with GFP and either Flag-LRRK2-R1441C,
Flag-LRRK2-WT, or vector plasmids at a 1:15 ratio were treated with FX2149 at 100 nM at 4 h post-transfection for 48 h. (A) Lysosomal events were quantified as
stationary, anterograde, or retrograde and expressed as a percentage of total lysosomes for DMSO and FX2149 treatments. *p < 0.05 by ANOVA compared to vector
control. {F (2, 7) = 8.18; F (2, 7) = 5.426; F (2, 7) = 5.510 for stationary, anterograde, retrograde, respectively}. #p < 0.05 by t-test compared to R1441C with vehicle
treatment. {F (4) = 2.18; F (4) = 1.399; F (4) = 1.778 for stationary, anterograde, retrograde, respectively}. (B) Quantification of total, anterograde, and retrograde run
lengths of lysosomes traveling at least 2 microns in FX2149 treated and DMSO treated cells. *p < 0.05 by ANOVA compared to vector control. {F (2, 103) = 4.249;
F (2, 32) = 0.4790; F (2, 79) = 5.747 for stationary, anterograde, retrograde run length, respectively}. #p < 0.05 by t-test compared to R1441C with vehicle treatment.
{F (36) = 2.003; F (10) = 2.705; F (24) = 1.500 for stationary, anterograde, retrograde run length, respectively}.
for mutant LRRK2-inducing mitochondrial dysfunctions and
thereby inducing neuritic injury, although this awaits further
investigation.
Mutant LRRK2 has been shown to cause lysosome/autophagic
pathway impairment (Alegre-Abarrategui and Wade-Martins,
2009; Henry et al., 2015; Esteves and Cardoso, 2016). A
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recent study has identified that LRRK2 mutations lead to
an increase in lysosomal size and a decrease in their ability
for degradation (Bandyopadhyay et al., 2014), as well as
impairs the autophagic cycle’s ability to clear toxic proteins
(Alegre-Abarrategui and Wade-Martins, 2009; Esteves and
Cardoso, 2016). A functioning axonal transport system is
necessary for the lysosome/autophagic pathway, as coordinated
lysosome and autophagosome positioning and recruitment
are prerequisites (Amaya et al., 2015). Our findings showed
that expression of mutant LRRK2 impairs lysosome transport
especially in the retrograde direction. These results demonstrate
that mutant LRRK2 disruption of lysosomal transport is
one of the early events in neuritic injury. LRRK2 has been
implicated as a crossroad for the autophagic clearance of
mitochondria (mitophagy) (Saez-Atienzar et al., 2014; Esteves
and Cardoso, 2016). PD-linked LRRK2 mutations can cause
a loss of mitochondrial membrane potential, which precedes
elimination by mitophagy, thereby resulting in a decrease in
available mitochondria for energy requirements (Su et al., 2015).
These mutations also dysregulate fission and fusion events,
leading to an increase in mitochondria fragmentation which
can trigger an excessive need for autophagy (Wang et al.,
2012; Su and Qi, 2013). Thus, mutant LRRK2 impairs both
mitochondrial and lysosomal transport, which could trigger
lysosome/autophagy pathway impairment resulting in eventual
degeneration.
The GTPase domain of LRRK2 has been previously identified
as a druggable entity, with GTP-binding inhibitors as potential
pharmaceutical candidates (Li et al., 2014, 2015). Pathological
LRRK2 mutations have been shown to lead to altered enzymatic
activities, and we recently have identified novel GTP-binding
inhibitors, 68 and FX2149, which reduces LRRK2 kinase activity
and protects against mutant-LRRK2-induced neurodegeneration
(Li et al., 2014; Raquel Esteves et al., 2014). In this study, we found
that 68 and FX2149 can significantly attenuate mutant LRRK2-
induced impairment of mitochondrial and lysosomal transport
in SH-SY5Y neurites. These findings suggest that LRRK2 GTP-
binding activity is critical for neuritic transport. The machinery
of intracellular organelle transport and how neurons specifically
regulate transport processes is a complex system (Chevalier-
Larsen and Holzbaur, 2006; Fu and Holzbaur, 2014; Maday
et al., 2014; Wong and Holzbaur, 2014). Kinesins and dynein
motor proteins participate in active anterograde and retrograde
transport, respectively, by “stepping” along microtubules (Maday
et al., 2014). This is done through an intricate process of
acetylation and deacetylation of the tubulin components of the
cytoskeleton, which the GTPase domain of LRRK2 has been
shown to affect (Godena et al., 2014; Law et al., 2014). LRRK2-
R1441C is in the GTPase domain and is implicated in disrupting
the balance of autophagic structures, which rely on functioning
transport systems (Alegre-Abarrategui et al., 2009; Orenstein
et al., 2013). Our studies with GTP-binding inhibitors, 68 and
FX2149, show an almost completely rescued lysosomal transport
impairment in these mutations, suggesting that GTPase domain
activity plays a critical role in mutant LRRK2-R1441C-induced
transport defects. LRRK2GTP-binding activity has been reported
as critical for LRRK2 action, and inhibition of GTP-binding
could ameliorate neurotoxicity resulting from R1441C-induced
dysfunction (Lewis et al., 2007; Xiong et al., 2010; Taymans, 2012;
Tsika and Moore, 2013). Pharmacological inhibition of GTP-
binding in LRRK2 could improve neural transport functions and
protect neurons against neurite injury and degeneration. These
findings further indicate that inhibition of GTP-binding activity
could be a valuable therapeutic approach for PD intervention.
In conclusion, our work demonstrates consequential
mitochondria and lysosome neuritic transport impairments as
a result of LRRK2-R1441C mutations, with a corresponding
neurite injury phenotype in SH-SY5Y cells. Inhibition of LRRK2
GTP-binding activity by compounds 68 and FX2149 improved
mutant LRRK2-R1441C-induced transport defects. As such,
targeting the GTP-binding region of LRRK2 may be a potential
therapy for LRRK2-related PD onset.
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